2 months ago

Zota Healthcare CEO on US Tariffs

Zota Healthcare CEO on US Tariffs
Indian generics will remain the most competitive on price and quality: Zota Healthcare CEO · CNBC TV 18

The US might put high taxes on generic drugs from India.

Dr. Sujit Paul, the CEO of Zota Healthcare, thinks Indian drug companies will still be the best in terms of price and quality.

He suggests that these companies should look for new markets, work more with US companies, and focus on making more complicated drugs.

This way, they can handle any problems caused by the US taxes.

Key facts

CEO
Dr. Sujit Paul
Company
Zota Healthcare
Potential Tariffs
Steep tariffs on generic drug imports
Indian Advantage
Cost and quality advantage
Strategic Recommendations
Diversify markets, expand US partnerships, focus on complex generics and biosimilars

Quotes

Dr. Sujit Paul

Chief executive officer of Zota Healthcare

“Indian generics will remain the most competitive on price and quality”
CNBC TV 18

Sources

Related news